ANW:FRA
Immuron Ltd
0,020 €
0,00%
(0,00) 1 D.
10-09, 08:03:28 GMT+2 · EUR
search
Visi simboliai
| Simbolis | Kaina | Keisti | Pokytis, % |
|---|
insights_autoGeneruojamos svarbiausios „ANW“ įžvalgos...
Atidaryti
0,02 €
Aukšta
0,02 €
Žema
0,02 €
Rinkos kapitalizacija
9,93 mln.
Vid. kiekis
627,00
Apimtis
0,00
52 sav. aukšta
0,04 €
52 sav. žema
0,01 €
Darbuotojų skaičius
8
Atidaryti
0,02 €
Aukšta
0,02 €
Žema
0,02 €
Rinkos kapitalizacija
9,93 mln.
Vid. kiekis
627,00
Apimtis
0,00
52 sav. aukšta
0,04 €
52 sav. žema
0,01 €
Darbuotojų skaičius
8
Naujienų istorijos
Iš žiniatinklio šaltinių ir naujienų partnerių
The Manila Times
·
prieš 43 minutes
Terminal1, the operating system built for public companies, announced today that U.S Gold Corp (NASDAQ:USAU) has joined the Terminal1 platform
Breakingthenews.net
·
prieš 14 minučių
Dow leads gains on Wall Street, surges 400 points
Investing.com
·
prieš 15 minučių
Moderna options activity surges as Nasdaq-100 inclusion and melanoma data drive call buying
Nasdaq
·
prieš 4 valandas
WISeSat.Space Holdings Corp. Rings the Opening Bell
Profilis
Immuron is a biotechnology company based in Melbourne, Australia. In 2008, the company changed its name to Immuron Limited, having previously operated as Anadis Limited.
Immuron is focused on antigen-primed and dairy-derived health products. Its proprietary technologies allow for rapid development of polyclonal antibody and other proteins-based solutions for a range of diseases. The company specialises in nutraceutical, pharmaceutical and therapeutic technology products for conditions such as oral and GI mucositis, avian influenza, E. coli travellers' diarrhoea and Anthrax containment.
In 2005, Anadis signed an agreement with Quebec's Baralex Inc. and Valeo Pharma Inc. for the distribution of Travelan, a product made by Anadis for the Canadian market. Wikipedia
Apie „Immuron Ltd“
Generalinis direktorius-
Darbuotojai8
Įkurta1994
Pagrindinė būstinėBlackburn North, Viktorija, Australija
Sektorius-
Svetainėimmuron.com.au